Venous blood sample: haematology and plasma micronutrient status, plus samples of serum, plasma and DNA are biobanked for future analyses.
These samples are then biobanked for future investigation which will include: (i) metabolic analyses (e.g. adiponectin, leptin, resistin), (ii) genetic analysis, (iii) gene expression analysis, and (iv) epigenetic analysis in peripheral blood mononuclear cells.
Blood samples are biobanked to facilitate future analyse of biomarkers, nutrients, DNA etc.
For 99% of included patients, preoperative blood samples are biobanked.
In addition, the biobank generated due to storage of remaining fecal material can be used for future reference to study e.g. yet unknown circulating microorganisms in day care with pathogenic potential.
Biobanks increasingly presume long-term storage of biomaterials and data that shall be used for future research projects which are today unspecified.
While registries are addressed in the document, recommendations are currently very broad; more specific guidance as to both registries and biobanks would be in order for future editions.
DNA and/or serum remaining after the RSV001 analyses have been performed are, with specific volunteer consent, to be transferred to the Oxford Vaccine Group BioBank for future seroepidemiological and other vaccine related research (ethics reference LREC 10/H0504/25).
Remaining material from the swab was prepared for future STI testing and stored in the Biobank at −80°C.
The establishment of a biobank in Denmark requires approval either by the Danish Data Protection Agency if data are stored for future use only, or by the EC if the biological data are to be used in the specific project.
